162 related articles for article (PubMed ID: 38416376)
1. EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.
Zhao R; Li J; Guo L; Xiang C; Chen S; Zhao J; Shao J; Zhu L; Ye M; Qin G; Chu T; Han Y
Target Oncol; 2024 Mar; 19(2):277-288. PubMed ID: 38416376
[TBL] [Abstract][Full Text] [Related]
2. A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes.
Chouaid C; Filleron T; Debieuvre D; Pérol M; Girard N; Dansin E; Lena H; Gervais R; Cousin S; Otto J; Schott R; Planchard D; Madroszyk A; Kaderbhai C; Dubray-Longeras P; Hiret S; Pichon E; Clément-Duchêne C; Chenuc G; Simon G; Bosquet L; QUantin X
Target Oncol; 2021 Nov; 16(6):801-811. PubMed ID: 34661827
[TBL] [Abstract][Full Text] [Related]
3. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review.
Burnett H; Emich H; Carroll C; Stapleton N; Mahadevia P; Li T
PLoS One; 2021; 16(3):e0247620. PubMed ID: 33684140
[TBL] [Abstract][Full Text] [Related]
4. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer
Kim TM; Girard N; Low GKM; Zhuo J; Yu DY; Yang Y; Murota M; Lim CTK; Kleinman NJ; Cho BC
Acta Oncol; 2023 Dec; 62(12):1689-1697. PubMed ID: 37938161
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
[TBL] [Abstract][Full Text] [Related]
6. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
[TBL] [Abstract][Full Text] [Related]
7. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
9. Clinical characterization of
Liu Z; Wu L; Cao J; Yang Z; Zhou C; Cao L; Wu H; Shen H; Jin M; Zhang Y; Mao X; Xiang J; Ma K; Li B; Zhang T; Hu Y
Onco Targets Ther; 2018; 11():7323-7331. PubMed ID: 30425522
[TBL] [Abstract][Full Text] [Related]
10. [First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient
with EGFR Exon 20 Insertion Mutantion].
Li Z; Wei T; Zeng D; Zhao L; Zhang J; Chen L
Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):241-244. PubMed ID: 38590198
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
[TBL] [Abstract][Full Text] [Related]
12. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
Nagasaka M; Singh V; Baca Y; Sukari A; Kim C; Mamdani H; Spira AI; Uprety D; Bepler G; Kim ES; Raez LE; Pai SG; Ikpeazu C; Oberley M; Feldman R; Xiu J; Korn WM; Wozniak AJ; Borghaei H; Liu SV
Clin Lung Cancer; 2022 Jan; 23(1):52-59. PubMed ID: 34801409
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
Gao J; Chen JQ; Zhang L; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
[TBL] [Abstract][Full Text] [Related]
14. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
Zhang Y; Wang Q; Han ZG; Shan L
Asian Pac J Cancer Prev; 2013; 14(5):2879-83. PubMed ID: 23803047
[TBL] [Abstract][Full Text] [Related]
15. ERBB2 exon 20 insertions are rare in Brazilian non-small cell lung cancer.
de Oliveira Cavagna R; Zaniolo BG; de Paula FE; Berardinelli GN; Santana I; da Silva ECA; Dias JM; Jacinto AA; da Nóbrega Oliveira REN; de Marchi P; Leal LF; Reis RM
Thorac Cancer; 2022 Dec; 13(23):3402-3407. PubMed ID: 36251951
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of
Shi L; Xu C; Ma Y; Ou Q; Wu X; Lu S; Shao Y; Guo R; Kong J
ESMO Open; 2020 Nov; 5(6):e000985. PubMed ID: 33214226
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
[TBL] [Abstract][Full Text] [Related]
18. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy.
Hondelink LM; Ernst SM; Atmodimedjo P; Cohen D; Wolf JL; Dingemans AC; Dubbink HJ; von der Thüsen JH
Eur J Cancer; 2023 Mar; 181():53-61. PubMed ID: 36638752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
